Yifeng Pharmacy Chain Co., Ltd.

SHSE:603939 Stock Report

Market Cap: CN¥27.4b

Yifeng Pharmacy Chain Valuation

Is 603939 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603939 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603939 (CN¥22.61) is trading below our estimate of fair value (CN¥97.36)

Significantly Below Fair Value: 603939 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603939?

Other financial metrics that can be useful for relative valuation.

603939 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA11.3x
PEG Ratio1x

Price to Earnings Ratio vs Peers

How does 603939's PE Ratio compare to its peers?

The above table shows the PE ratio for 603939 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.5x
603233 DaShenLin Pharmaceutical Group
18.2x22.8%CN¥16.5b
603883 LBX Pharmacy Chain
13.4x17.7%CN¥12.3b
002727 Yixintang Pharmaceutical Group
24.1x31.5%CN¥8.1b
605266 Jianzhijia Pharmaceutical Chain Group
10.5x27.3%CN¥3.3b
603939 Yifeng Pharmacy Chain
18.2x18.9%CN¥27.4b

Price-To-Earnings vs Peers: 603939 is expensive based on its Price-To-Earnings Ratio (18.2x) compared to the peer average (16.5x).


Price to Earnings Ratio vs Industry

How does 603939's PE Ratio compare vs other companies in the CN Consumer Retailing Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a37.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a37.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 603939 is good value based on its Price-To-Earnings Ratio (18.2x) compared to the CN Consumer Retailing industry average (26.4x).


Price to Earnings Ratio vs Fair Ratio

What is 603939's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603939 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.2x
Fair PE Ratio26x

Price-To-Earnings vs Fair Ratio: 603939 is good value based on its Price-To-Earnings Ratio (18.2x) compared to the estimated Fair Price-To-Earnings Ratio (26x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603939 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥22.61
CN¥36.75
+62.5%
20.3%CN¥48.33CN¥25.00n/a14
Oct ’25CN¥25.52
CN¥37.27
+46.0%
20.1%CN¥48.33CN¥25.00n/a14
Sep ’25CN¥20.17
CN¥41.66
+106.5%
11.0%CN¥48.33CN¥29.90n/a13
Aug ’25CN¥20.14
CN¥42.98
+113.4%
7.7%CN¥48.33CN¥37.30n/a13
Jul ’25CN¥25.61
CN¥44.33
+73.1%
8.0%CN¥48.33CN¥37.30n/a13
Jun ’25CN¥37.55
CN¥44.70
+19.0%
6.4%CN¥48.33CN¥39.63n/a13
May ’25CN¥36.62
CN¥43.38
+18.5%
7.3%CN¥47.17CN¥36.50n/a10
Apr ’25CN¥33.30
CN¥43.02
+29.2%
7.8%CN¥48.33CN¥36.50n/a12
Mar ’25CN¥32.96
CN¥42.74
+29.7%
8.1%CN¥48.33CN¥36.50n/a11
Feb ’25CN¥32.18
CN¥42.74
+32.8%
8.1%CN¥48.33CN¥36.50n/a11
Jan ’25CN¥33.37
CN¥39.80
+19.3%
15.0%CN¥48.33CN¥27.98n/a11
Dec ’24CN¥31.96
CN¥39.73
+24.3%
14.8%CN¥48.33CN¥27.98n/a11
Nov ’24CN¥28.61
CN¥39.84
+39.3%
14.2%CN¥48.33CN¥27.98n/a12
Oct ’24CN¥29.23
CN¥40.57
+38.8%
14.4%CN¥48.33CN¥27.98CN¥25.5212
Sep ’24CN¥29.17
CN¥39.58
+35.7%
13.4%CN¥48.33CN¥27.98CN¥20.1712
Aug ’24CN¥32.10
CN¥37.68
+17.4%
14.3%CN¥48.33CN¥27.98CN¥20.1411
Jul ’24CN¥30.83
CN¥38.42
+24.6%
13.0%CN¥45.83CN¥27.98CN¥25.6111
Jun ’24CN¥29.66
CN¥39.83
+34.3%
12.2%CN¥45.83CN¥27.98CN¥37.5510
May ’24CN¥29.65
CN¥40.13
+35.3%
14.9%CN¥45.83CN¥26.79CN¥36.628
Apr ’24CN¥34.42
CN¥39.90
+15.9%
16.6%CN¥49.40CN¥26.79CN¥33.308
Mar ’24CN¥35.31
CN¥40.27
+14.0%
17.2%CN¥49.40CN¥26.79CN¥32.968
Feb ’24CN¥34.58
CN¥39.90
+15.4%
16.6%CN¥49.40CN¥26.79CN¥32.188
Jan ’24CN¥38.00
CN¥37.77
-0.6%
15.5%CN¥45.83CN¥26.79CN¥33.377
Dec ’23CN¥39.89
CN¥37.77
-5.3%
15.5%CN¥45.83CN¥26.79CN¥31.967
Nov ’23CN¥33.92
CN¥37.26
+9.8%
14.1%CN¥44.05CN¥26.79CN¥28.617
Oct ’23CN¥29.62
CN¥37.26
+25.8%
14.1%CN¥44.05CN¥26.79CN¥29.237

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies